In addition to platinum analogues, the FDA approval of anti-PD-L1 therapy (given as single agent in ~15% of cases or with a platinum in ~85% of NSCLC cases) for first-line treatment of NSCLC has led to substantial clinical benefits for patients [3]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.